Cover Image
Market Research Report

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 363563
Published Content info 68 Pages
Delivery time: 1-2 business days
Price
Back to Top
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019
Published: April 29, 2019 Content info: 68 Pages
Description

Summary:

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2019, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Filing rejected/Withdrawn, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory which include indications Alzheimer's Disease, Autoimmune Disorders, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Pain, Periodontitis and Rheumatoid Arthritis.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1862TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
    • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
    • AFFiRiS AG
    • ChemoCentryx Inc
    • Dompe Farmaceutici SpA
    • Innate Pharma SA
    • Integral Molecular Inc
    • MorphoSys AG
    • Prommune Inc
    • Teva Pharmaceutical Industries Ltd
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
    • ALS-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DF-2593A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize C5aR for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EP-67 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPH-5401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize C5AR1 for Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOR-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMX-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target C5a for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 24, 2019: ChemoCentryx announces withdrawal of phase II-based conditional marketing authorisation (CMA) application for ANCA-associated vasculitis in Europe, phase III advocate trial data release planned for Q4 2019
      • Oct 25, 2018: ChemoCentryx announces presentation of data on Avacopan, a complement 5a receptor inhibitor, at ASN Kidney Week 2018
      • Sep 12, 2018: Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi) in solid tumors
      • May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
      • Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
      • Jan 04, 2018: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
      • Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
      • Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference
      • Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
      • May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
      • Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
      • Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
      • Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
      • Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
      • Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Indications, H1 2019
  • Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Investigation by Universities/Institutes, H1 2019
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pipeline by AFFiRiS AG, H1 2019
  • Pipeline by ChemoCentryx Inc, H1 2019
  • Pipeline by Dompe Farmaceutici SpA, H1 2019
  • Pipeline by Innate Pharma SA, H1 2019
  • Pipeline by Integral Molecular Inc, H1 2019
  • Pipeline by MorphoSys AG, H1 2019
  • Pipeline by Prommune Inc, H1 2019
  • Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
  • Dormant Products, H1 2019
  • Dormant Products, H1 2019 (Contd..1), H1 2019
  • Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Top 10 Indications, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top